NAUT

Nautilus Biotechnolgy, Inc. (NAUT) SWOT Analysis Analysis (2026)

Invetso Score: 3.3/10 — Weak · Last Updated: 2026-09-01

Strengths

Strong liquidity with a current ratio of 10.14x and cash ratio of 1.52x.

Balance sheet remains conservative with debt-to-equity at 0.21x and debt-to-assets at 0.17x.

Net current asset value is positive at $55.2M, supporting downside protection.

Weaknesses

Profitability remains deeply negative, with net profit margin at -297.5% and operating margin at -330.4%.

Returns are poor across the board, including ROE at -37.6% and ROIC at -39.5%.

Cash generation is negative, with free cash flow yield at -42.4% and operating cash flow ratio at -5.81x.

Revenue efficiency is extremely weak, with asset turnover at 0.0012x and price-to-sales at 644.2x.

Opportunities

If the company can convert its strong liquidity into operating scale, the balance sheet provides room to fund growth.

Positive net current asset value and low leverage could support strategic flexibility or restructuring options.

Any improvement in operating discipline could have an outsized impact given the currently depressed earnings base.

Threats

Sustained losses and negative cash flow create ongoing dilution or financing risk if operations do not improve.

Extremely high valuation multiples, including EV/sales at 721.3x, leave little room for execution disappointment.

Negative solvency ratio and weak operating cash flow coverage highlight continued financial fragility.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nautilus Biotechnolgy, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →